Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Processa Pharmaceuticals ( (PCSA) ) just unveiled an announcement.
On June 17, 2025, Processa Pharmaceuticals announced the pricing of a public offering involving 28,000,000 shares of common stock and associated warrants, expected to raise $7 million before expenses. The offering, which closed on June 18, 2025, aims to fund the Phase 2 clinical trial of NGC-Cap and other corporate purposes, potentially impacting the company’s operational capabilities and market positioning.
The most recent analyst rating on (PCSA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Processa Pharmaceuticals stock, see the PCSA Stock Forecast page.
Spark’s Take on PCSA Stock
According to Spark, TipRanks’ AI Analyst, PCSA is a Underperform.
Processa Pharmaceuticals is facing significant financial challenges with no revenue generation and ongoing losses. Technical indicators point to bearish momentum, and valuation metrics highlight the high-risk nature typical of early-stage biotech firms. The company’s reliance on external financing for sustainability remains a concern.
To see Spark’s full report on PCSA stock, click here.
More about Processa Pharmaceuticals
Processa Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on developing Next Generation Cancer (NGC) drugs with improved safety and efficacy. Their NGC drugs are modifications of existing FDA-approved oncology therapies, aimed at altering the metabolism and/or distribution of these drugs while maintaining their cancer-killing mechanisms. The company’s strategy involves combining novel oncology pipelines with proven cancer-killing active molecules to develop more effective and tolerable therapy options for cancer patients through an efficient regulatory path.
Average Trading Volume: 13,849,773
Technical Sentiment Signal: Strong Sell
Current Market Cap: $2.68M
Find detailed analytics on PCSA stock on TipRanks’ Stock Analysis page.